Projected life expectancy of people with HIV according to timing of diagnosis
暂无分享,去创建一个
Andrew N. Phillips | Jens D. Lundgren | Valentina Cambiano | A. Phillips | J. Lundgren | Colette Smith | Fumiyo Nakagawa | Rebecca K. Lodwick | Colette J. Smith | Ruth Smith | Valerie Delpech | R. Lodwick | V. Cambiano | Ruth D Smith | V. Delpech | F. Nakagawa | Ruth D. Smith
[1] J Elford,et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. , 1991, Journal of acquired immune deficiency syndromes.
[2] L. Kuller,et al. Cigarette smoking and mortality , 1991 .
[3] C. Sabin,et al. Immunodeficiency and the risk of death in HIV infection. , 1992, JAMA.
[4] I. Keet,et al. Prognostic Value of HIV-1 Syncytium-Inducing Phenotype for Rate of CD4+ Cell Depletion and Progression to AIDS , 1993, Annals of Internal Medicine.
[5] J. Nielsen,et al. Survival differences in European patients with AIDS, 1979–89 , 1994, BMJ.
[6] J J Goedert,et al. Natural history of HIV-1 cell-free viremia. , 1995, JAMA.
[7] Roger Detels,et al. Plasma Viral Load and CD4+ Lymphocytes as Prognostic Markers of HIV-1 Infection , 1997, Annals of Internal Medicine.
[8] G. Satten,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.
[9] A. Hatzakis,et al. Determinants of progression of HIV infection in a Greek hemophilia cohort followed for up to 16 years after seroconversion. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[10] J J Goedert,et al. Longitudinal HIV-1 RNA levels in a cohort of homosexual men. , 1998, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.
[11] J. Goedert,et al. Effects of age at seroconversion and baseline HIV RNA level on the loss of CD4+ cells among persons with hemophilia , 1998, AIDS.
[12] P. Kissinger,et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. , 1998, The New England journal of medicine.
[13] C. Sabin,et al. Determinants of sustainable CD4 lymphocyte count increases in response to antiretroviral therapy. , 1999, AIDS.
[14] A. Telenti,et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study , 1999, The Lancet.
[15] C. Sabin,et al. Virological response to protease inhibitor therapy in an HIV clinic cohort. , 1999, AIDS.
[16] R. Manfredi,et al. Viral load trend in HIV-1 seropositive patients with different CD4 cell counts before starting HAART. , 2000, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.
[17] Hiv Survival,et al. Time from HIV-1 seroconversion to AIDS and death before widespread use of highly-active antiretroviral therapy: a collaborative re-analysis , 2000, The Lancet.
[18] Susan Swindells,et al. Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection , 2000, Annals of Internal Medicine.
[19] A. Phillips,et al. Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens , 2000, AIDS.
[20] C. Rouzioux,et al. Natural history of serum HIV-1 RNA levels in 330 patients with a known date of infection , 2000, AIDS.
[21] C. Sabin,et al. Course of Viral Load Throughout HIV‐1 Infection , 2000, Journal of acquired immune deficiency syndromes.
[22] S. Hammer,et al. The Relation between Baseline HIV Drug Resistance and Response to Antiretroviral Therapy: Re-Analysis of Retrospective and Prospective Studies Using a Standardized Data Analysis Plan , 2000, Antiviral therapy.
[23] C. Sabin,et al. Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre , 2001, AIDS.
[24] S. Danner,et al. Adherence over 48 Weeks in An Antiretroviral Clinical Trial: Variable within Patients, Affected by Toxicities and Independently Predictive of Virological Response , 2000, Antiviral therapy.
[25] K. Juel,et al. Abstention from smoking extends life and compresses morbidity: a population based study of health expectancy among smokers and never smokers in Denmark , 2001, Tobacco control.
[26] M. Johnson,et al. Replicative fitness in vivo of HIV‐1 variants with multiple drug resistance‐associated mutations , 2001, Journal of medical virology.
[27] R Weber,et al. HIV viral load response to antiretroviral therapy according to the baseline CD4 cell count and viral load. , 2001, JAMA.
[28] A. Sönnerborg,et al. Kinetics of HIV-1 RNA and resistance-associated mutations after cessation of antiretroviral combination therapy , 2001, AIDS.
[29] Jacques Izopet,et al. Changes in Human Immunodeficiency Virus Type 1 Populations after Treatment Interruption in Patients Failing Antiretroviral Therapy , 2001, Journal of Virology.
[30] J. Goedert,et al. Association of cancer with AIDS-related immunosuppression in adults. , 2001, JAMA.
[31] Sundhiya Mandalia,et al. Responses to a 1 month self-report on adherence to antiretroviral therapy are consistent with electronic data and virological treatment outcome , 2002, AIDS.
[32] P. Tebas,et al. Effect of prolonged discontinuation of successful antiretroviral therapy on CD4+ T cell decline in human immunodeficiency virus-infected patients: implications for intermittent therapeutic strategies. , 2002, The Journal of infectious diseases.
[33] Jonathan AC Sterne,et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies , 2002, The Lancet.
[34] B. Schmidt,et al. No evidence for persistence of multidrug-resistant viral strains after a 7-month treatment interruption in an HIV-1-infected individual. , 2002, Journal of acquired immune deficiency syndromes.
[35] A. Trkola,et al. HIV RNA in plasma rebounds within days during structured treatment interruptions , 2003, AIDS.
[36] J. Gallant,et al. Prolonged treatment interruption after immunologic response to highly active antiretroviral therapy. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[37] Mark S Roberts,et al. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era , 2003, Medical decision making : an international journal of the Society for Medical Decision Making.
[38] D. Costagliola,et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[39] Terri Wrin,et al. Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response , 2003, AIDS.
[40] A. Mocroft,et al. Virological rebound after suppression on highly active antiretroviral therapy , 2003, AIDS.
[41] J. Moatti,et al. Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study , 2002, Antiviral therapy.
[42] Gary Collins,et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. , 2003, The New England journal of medicine.
[43] Rodolphe Thiébaut,et al. Combination antiretroviral therapy and the risk of myocardial infarction , 2003 .
[44] D. Bangsberg,et al. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. , 2004, The Journal of antimicrobial chemotherapy.
[45] Bruno Ledergerber,et al. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes , 2004, The Lancet.
[46] D. Bangsberg,et al. Modeling the HIV protease inhibitor adherence-resistance curve by use of empirically derived estimates. , 2004, The Journal of infectious diseases.
[47] Joel E Gallant,et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. , 2004, JAMA.
[48] C. Tinelli,et al. CD4+ cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy , 2004, AIDS.
[49] D. Skiest,et al. It Is Safe to Stop Antiretroviral Therapy in Patients With Preantiretroviral CD4 Cell Counts >250 cells/μL , 2004, Journal of acquired immune deficiency syndromes.
[50] A. Phillips,et al. Short-term risk of AIDS according to current CD4 cell count and viral load in antiretroviral drug-naive individuals and those treated in the monotherapy era , 2003, AIDS.
[51] N. Pantazis,et al. Differences in HIV RNA levels before the initiation of antiretroviral therapy among 1864 individuals with known HIV-1 seroconversion dates , 2004, AIDS.
[52] B. Gazzard,et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study , 2004, The Lancet.
[53] P. Harrigan,et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. , 2005, The Journal of infectious diseases.
[54] M. Knoll,et al. Extended antiretroviral treatment interruption in HIV‐infected patients with long‐term suppression of plasma HIV RNA , 2005, HIV medicine.
[55] M. Moroni,et al. Interruption of Highly Active Antiretroviral Therapy in HIV Clinical Practice: Results From the Italian Cohort of Antiretroviral-Naive Patients , 2005, Journal of acquired immune deficiency syndromes.
[56] F. Wit,et al. Safety of long-term interruption of successful antiretroviral therapy: the ATHENA cohort study , 2005, AIDS.
[57] Jonathan AC Sterne,et al. Long-term effectiveness of potent antiretroviral therapy in preventing AIDS and death: a prospective cohort study , 2005, The Lancet.
[58] Nikos Pantazis,et al. Bivariate modelling of longitudinal measurements of two human immunodeficiency type 1 disease progression markers in the presence of informative drop‐outs , 2005 .
[59] Mark S Roberts,et al. Estimating the proportion of patients infected with HIV who will die of comorbid diseases. , 2005, The American journal of medicine.
[60] B. Gazzard,et al. The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study. , 2005, The Journal of infectious diseases.
[61] B. Gazzard,et al. Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice , 2005, AIDS.
[62] J. Margolick,et al. Interruption and Discontinuation of Highly Active Antiretroviral Therapy in the Multicenter AIDS Cohort Study , 2005, Journal of acquired immune deficiency syndromes.
[63] H. Fleury,et al. Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 106 cells/l , 2005, AIDS.
[64] Milton C Weinstein,et al. Expanded screening for HIV in the United States--an analysis of cost-effectiveness. , 2005, The New England journal of medicine.
[65] M. Lederman,et al. Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects. , 2005, The Journal of infectious diseases.
[66] A. Mocroft,et al. Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection. , 2005, AIDS research and human retroviruses.
[67] Jonathan A C Sterne,et al. HIV treatment response and prognosis in Europe and North America in the first decade of highly active antiretroviral therapy: a collaborative analysis , 2006, The Lancet.
[68] Milton C Weinstein,et al. The Lifetime Cost of Current Human Immunodeficiency Virus Care in the United States , 2006, Medical care.
[69] J. Gatell,et al. Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002. , 2006, Archives of internal medicine.
[70] J. Stockman. Expanded Screening for HIV in the United States—an Analysis of Cost-effectiveness , 2006 .
[71] A. Mocroft,et al. Regional Changes Over Time in Initial Virologic Response Rates to Combination Antiretroviral Therapy Across Europe , 2006, Journal of acquired immune deficiency syndromes.
[72] C. Sabin,et al. The late diagnosis and consequent short-term mortality of HIV-infected heterosexuals (England and Wales, 2000–2004) , 2006, AIDS.
[73] Milton C Weinstein,et al. The survival benefits of AIDS treatment in the United States. , 2006, The Journal of infectious diseases.
[74] C. Sabin,et al. Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004. , 2007, Archives of internal medicine.
[75] Ewout W Steyerberg,et al. Associations of diabetes mellitus with total life expectancy and life expectancy with and without cardiovascular disease. , 2007, Archives of internal medicine.
[76] B. Gazzard,et al. Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study , 2007, The Lancet.
[77] Gitte Pedersen,et al. Survival of Persons with and without HIV Infection in Denmark, 19952005 , 2007, Annals of Internal Medicine.
[78] J. Lundgren,et al. HIV in the UK 1980–2006: reconstruction using a model of HIV infection and the effect of antiretroviral therapy , 2007, HIV medicine.
[79] S. Twu,et al. Life expectancy of patients with newly-diagnosed HIV infection in the era of highly active antiretroviral therapy. , 2006, QJM : monthly journal of the Association of Physicians.
[80] C. Latkin,et al. Correlates of Lending Needles/Syringes Among HIV-Seropositive Injection Drug Users , 2007, Journal of acquired immune deficiency syndromes.
[81] A. Phillips,et al. Temporal trends in postseroconversion CD4 cell count and HIV load: the Concerted Action on Seroconversion to AIDS and Death in Europe Collaboration, 1985-2002. , 2007, The Journal of infectious diseases.
[82] C. Katlama,et al. HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population , 2007, Journal of acquired immune deficiency syndromes.
[83] C. Sabin,et al. Stability of antiretroviral regimens in patients with viral suppression , 2008, AIDS.
[84] Ross J. Harris,et al. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies , 2008, The Lancet.
[85] F. Raffi,et al. European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV‐infected adults , 2008, HIV medicine.
[86] O. Kirk,et al. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration , 2008, The Lancet.
[87] D. Pillay,et al. What is the risk of mortality following diagnosis of multidrug-resistant HIV-1? , 2008, The Journal of antimicrobial chemotherapy.
[88] A. Phillips,et al. The role of HIV in serious diseases other than AIDS , 2008, AIDS.
[89] B. Gazzard. British HIV Association guidelines for the treatment of HIV‐1‐infected adults with antiretroviral therapy 2008 , 2005, HIV medicine.
[90] John T Brooks,et al. Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. , 2009, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.
[91] R. Weber,et al. Association of noncirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[92] E. Ricci,et al. Cardiovascular risk assessment in antiretroviral-naïve HIV patients. , 2009, AIDS patient care and STDs.
[93] B. Yip,et al. The Combined Effect of Modern Highly Active Antiretroviral Therapy Regimens and Adherence on Mortality Over Time , 2009, Journal of acquired immune deficiency syndromes.
[94] D. Francisci,et al. HIV type 1 infection, and not short-term HAART, induces endothelial dysfunction , 2009, AIDS (London).
[95] A. Phillips,et al. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity , 2009, BMJ : British Medical Journal.
[96] A. Phillips,et al. Long-term trends in adherence to antiretroviral therapy from start of HAART , 2010, AIDS.
[97] M. Fisher. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μL in Europe and North America: a pooled cohort observational study , 2010, The Lancet.
[98] Coris,et al. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per microL in Europe and North America: a pooled cohort observational study , 2010 .
[99] Peter Reiss,et al. Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals , 2010, AIDS.
[100] C. Leen,et al. Trends over calendar time in antiretroviral treatment success and failure in HIV clinic populations * , 2010, HIV medicine.
[101] A. Mocroft,et al. Chronic Kidney Disease and Exposure to ART in a large cohort with Long-term Follow-up: The EuroSIDA study , 2010 .
[102] P. Volberding,et al. Antiretroviral therapy and management of HIV infection , 2010, The Lancet.
[103] Xinjiang Zhang,et al. Life Expectancy After HIV Diagnosis Based on National HIV Surveillance Data From 25 States, United States , 2010, Journal of acquired immune deficiency syndromes.
[104] Delpech,et al. Long-term probability of detecting drug-resistant HIV in treatment-naive patients initiating combination antiretroviral therapy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[105] P. Harrigan,et al. Improved virological outcomes in British Columbia concomitant with decreasing incidence of HIV type 1 drug resistance detection. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.